Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2026)

Design Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $230.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 2.96% year-over-year to $230.4 million; the TTM figure through Mar 2026 stood at $891.3 million (down 12.68% YoY), while the FY2025 annual figure was $226.2 million, down 10.27% from the prior year.
• Liabilities and Shareholders Equity came in at $230.4 million for Q1 2026 at Design Therapeutics, up from $226.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $378.8 million in Q1 2022 to a low of $211.8 million in Q3 2025.
• A 5-year average of $285.8 million and a median of $278.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity fell 19.06% in 2025 and declined 2.96% in 2026, its largest moves.
• Design Therapeutics' Liabilities and Shareholders Equity stood at $341.1 million in 2022, then dropped by 15.09% to $289.6 million in 2023, then dropped by 12.96% to $252.1 million in 2024, then slipped by 10.27% to $226.2 million in 2025, then rose by 1.87% to $230.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $230.4 million, $226.2 million, and $211.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison